175 related articles for article (PubMed ID: 30951287)
21. Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia.
Wang WT; Han C; Sun YM; Chen ZH; Fang K; Huang W; Sun LY; Zeng ZC; Luo XQ; Chen YQ
Clin Cancer Res; 2019 May; 25(9):2795-2808. PubMed ID: 30651276
[TBL] [Abstract][Full Text] [Related]
22. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
[TBL] [Abstract][Full Text] [Related]
23. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
Sarno F; Nebbioso A; Altucci L
Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
[TBL] [Abstract][Full Text] [Related]
24. DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation.
Song T; Zou Q; Yan Y; Lv S; Li N; Zhao X; Ma X; Liu H; Tang B; Sun L
Cell Rep; 2021 Sep; 36(12):109739. PubMed ID: 34551297
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
Bon C; Si Y; Pernak M; Barbachowska M; Levi-Acobas E; Cadet Daniel V; Jallet C; Ruzic D; Djokovic N; Djikić T; Nikolic K; Halby L; Arimondo PB
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500733
[TBL] [Abstract][Full Text] [Related]
26. DOT1L activity in leukemia cells requires interaction with ubiquitylated H2B that promotes productive nucleosome binding.
Spangler CJ; Yadav SP; Li D; Geil CN; Smith CB; Wang GG; Lee TH; McGinty RK
Cell Rep; 2022 Feb; 38(7):110369. PubMed ID: 35172132
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
Chen C; Zhu H; Stauffer F; Caravatti G; Vollmer S; Machauer R; Holzer P; Möbitz H; Scheufler C; Klumpp M; Tiedt R; Beyer KS; Calkins K; Guthy D; Kiffe M; Zhang J; Gaul C
ACS Med Chem Lett; 2016 Aug; 7(8):735-40. PubMed ID: 27563395
[TBL] [Abstract][Full Text] [Related]
28. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9.
Secker KA; Keppeler H; Duerr-Stoerzer S; Schmid H; Schneidawind D; Hentrich T; Schulze-Hentrich JM; Mankel B; Fend F; Schneidawind C
Oncogene; 2019 Nov; 38(46):7181-7195. PubMed ID: 31417187
[TBL] [Abstract][Full Text] [Related]
30. Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.
Waters NJ
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):891-901. PubMed ID: 28229434
[TBL] [Abstract][Full Text] [Related]
31. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
Anglin JL; Song Y
J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
[TBL] [Abstract][Full Text] [Related]
32. The upstreams and downstreams of H3K79 methylation by DOT1L.
Vlaming H; van Leeuwen F
Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
[TBL] [Abstract][Full Text] [Related]
34. Novel DOT1L ReceptorNatural Inhibitors Involved in Mixed Lineage Leukemia: a Virtual Screening, Molecular Docking and Dynamics Simulation Study.
Raj U; Kumar H; Gupta S; Varadwaj PK
Asian Pac J Cancer Prev; 2015; 16(9):3817-25. PubMed ID: 25987043
[TBL] [Abstract][Full Text] [Related]
35. The diverse functions of Dot1 and H3K79 methylation.
Nguyen AT; Zhang Y
Genes Dev; 2011 Jul; 25(13):1345-58. PubMed ID: 21724828
[TBL] [Abstract][Full Text] [Related]
36. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
37. The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
Wong M; Polly P; Liu T
Am J Cancer Res; 2015; 5(9):2823-37. PubMed ID: 26609488
[TBL] [Abstract][Full Text] [Related]
38. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
Barry ER; Corry GN; Rasmussen TP
Expert Opin Ther Targets; 2010 Apr; 14(4):405-18. PubMed ID: 20230194
[TBL] [Abstract][Full Text] [Related]
39. Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.
Scheufler C; Möbitz H; Gaul C; Ragot C; Be C; Fernández C; Beyer KS; Tiedt R; Stauffer F
ACS Med Chem Lett; 2016 Aug; 7(8):730-4. PubMed ID: 27563394
[TBL] [Abstract][Full Text] [Related]
40. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
Gibbons GS; Owens SR; Fearon ER; Nikolovska-Coleska Z
ACS Chem Biol; 2015 Jan; 10(1):109-14. PubMed ID: 25361163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]